SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced the acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The poster will detail a study on the efficacy and safety of galinpepimut-S (GPS) maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line therapy. The study, led by Dr. Omer Jamy, Principal Investigator, will be presented on June 5, 2023. Additionally, SELLAS is advancing its cancer therapies, notably GPS, targeting the WT1 protein across various malignancies, and GFH009, a CDK9 inhibitor licensed from GenFleet Therapeutics.
- Acceptance of an abstract for a poster presentation at ASCO, boosting visibility.
- Focus on advanced cancer therapies, including GPS and GFH009, indicates growth potential.
- None.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually.
Presentation Details:
Title: “A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.”
Presenter: Omer Jamy, M.D. Principal Investigator of REGAL Study at the University of Alabama at Birmingham
Presentation Type: Poster
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Clinical Trial Registration Number: NCT04229979
Abstract Number: TPS7074
Session Date and Time: Monday, June 5, 2023, 9:00 AM – 12:00 PM EDT
Location: Hall A, On Demand
The full abstract will be published by ASCO on May 25, 2023 at 5:00 pm EDT.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 16, 2023 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
FAQ
What is the significance of the poster presentation by SELLAS Life Sciences at ASCO 2023?
When will SELLAS present its findings on galinpepimut-S for AML?
What is the clinical trial registration number for the galinpepimut-S study?
What type of therapy is galinpepimut-S being studied for?
Who is the principal investigator for the galinpepimut-S study?
What is SELLAS Life Sciences’ lead product candidate?
